HERIZON-GEA-01: Zanidatamab + chemo?? tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
HERIZON-GEA-01: Zanidatamab + chemo?? tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022 Sep; 18(29):3255-3266.